BACKGROUND: To investigate prognostic factors of recent submacular haemorrhage (SMH) complicating neovascular age-related macular degeneration (nAMD) treated with surgery or pneumatic displacement combined with intravitreal injection of anti-vascular endothelial growth factor. METHODS: Post hoc analysis of the STAR randomised controlled trial data evaluating the influence of baseline clinical and imaging characteristics on visual outcomes over 6 months using multivariate generalised additive mixed models. RESULTS: Patients with worse baseline visual acuity (VA) had faster (estimated degree of freedom EDF = 2.87, p 1000 μm) and greater predicted visual improvement (difference = +13.5 3.66; 23.39 letters between ≤ 1000 and > 1000 μm, p 1000 μm, p < 0.001). Interactions between the treatment group and both VA and SMH thickness were non-significant. CONCLUSION: Better VA and lower SMH thickness at baseline were significantly associated with better visual outcomes over 6 months, independently of treatment arm in SMH complicating nAMD. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02557451.
Gabrielle et al. (Tue,) studied this question.